This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

ESMO-Asia, Singapore 22-24 November 2019

A Phase IIIb open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: exploratory biomarker analysis​

Jie Wang, Jun Zhao, Hua Bai, Xin Wang, Yuyan Wang, Jianchun Duan, Hanxiao Chen, Susan Meng, Yahui Tian, Dennis Chin-Lun Huang, Yi-Long Wu

1200.66_biomarkers_encore_esmo_asia_2019.jpg

Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

A Phase IIIb open-label, single-arm study of afatinib in EGFR TKI-naïve patients with EGFRm+ NSCLC: An interim analysis

Wu Y-L, et al. WCLC 2017. P3.01-036

The value of real-world evidence to clinical practice

Real-world evidence complements clinical trials by providing information on the effectiveness and side-effect profile of therapies in patients treated in routine clinical practice.

The value of real-world evidence to clinical practice

Rate this

FOR HEALTHCARE PROFESSIONALS ONLY

image